MedPath

A Study to Evaluate the Effectiveness and Safety of ExAblate MRgFUS on Essential Tremor

Not Applicable
Terminated
Conditions
Essential Tremor
Interventions
Device: MRgFUS treatment
Registration Number
NCT03253991
Lead Sponsor
InSightec
Brief Summary

A Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects

The objective of this prospective, single-arm study is to test the efficacy of treatment using the ExAblate Transcranial System and to further demonstrate safety in medication-refractory tremor inpatients with essential tremor (ET).

The Indications for Use claim for this system is as follows: Treatment of medication-refractory tremor in patients with essential tremor.

Detailed Description

The objective of this prospective, multi-site, single-arm study is to test the efficacy of treatment using the ExAblate Transcranial System and to further demonstrate safety in medication-refractory tremor in subjects with essential tremor (ET).

Safety: To evaluate the incidence and severity of adverse events (AE/AEs) associated with ExAblate Transcranial MRgFUS treatment of medication-refractory ET Effectiveness: To determine the effectiveness of the ExAblate Transcranial MRgFUS treatment of medication-refractory tremor (i.e. ET). Efficacy will be determined utilizing the Clinical Rating Scale for Tremor (CRST) in ET from examinations at baseline and 3-Months post-ExAblate treatment.

• This study is designed as a prospective, multi-site, single-arm study. Assessments of primary efficacy endpoints will compare the three months after ExAblate treatment to Baseline measurements for clinical symptom relief. Safety of ExAblate in the treatment of ET will be collected for one year after ExAblate treatment. Relative Safety will be evaluated using a common description of Significant Clinical Complications for patients treated in this study. This study will be performed on the 3T MR scanners.

The secondary endpoints of the study are as follows:

1. Quality life claims: Questionnaire for Essential Tremor (QUEST) outcome (upper extremity questions) at Months 3 change from Baseline

2. Durability (as measured by QUEST upper arm extremity questions) of the procedure as reflected by the efficacy data through change from baseline measures through Month 12 follow up

3. Subject daily functionalities: as measured by CRST Part-C (subscales)Month 12 as compared to Baseline.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
154
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
MRgFUS treatmentMRgFUS treatmentMRgFUS device treatment, thalamotomy
Primary Outcome Measures
NameTimeMethod
Safety - Will be determined evaluating incidence and severity of device related complications from first treatment day visit through all follow ups. Relative Safety will be evaluated describing Significant Clinical Complications for patients treated.1 year

All AEs will be reported and categorized by investigators as definitely, probably, possibly, or unrelated to the device or procedure and categorized by treatment group / treatment arm. Relative Safety will be evaluated using a common description of Significant Clinical Complications for patients treated in this study.

Effectiveness - Will be evaluated using the Clinical Rating Scale for Tremors (CRST) for ET subjects. Comparison will be performed from examinations at baseline and 3-Months post-ExAblate treatment.5 Years

Assessments of efficacy endpoints will compare the three months after ExAblate treatment to Baseline measurements for clinical symptom relief.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (11)

Henan Provincial People's Hospital

🇨🇳

Zhengzhou, Henan, China

Tokyo Women's Medical University Hospital

🇯🇵

Tokyo, Japan

Department of Neurosurgery, Osaka University Hospital

🇯🇵

Osaka, Japan

Chinese PLA General Hospital

🇨🇳

Beijing, Beijing, China

Shonan Fujisawa Tokushukai Hospital

🇯🇵

Fujisawa, Japan

Sadamoto Hospital

🇯🇵

Ehime, Japan

Hokkaido Ohno Memorial Hospital

🇯🇵

Hokkaido, Japan

Hokuto

🇯🇵

Hokkaido, Japan

Kumagaya General Hospital

🇯🇵

Kumagaya, Japan

Ohanishi Noerological Center

🇯🇵

Hyōgo, Japan

Chang Bing Show Chwan Memorial Hospital

🇨🇳

Chang Hua, Taiwan

© Copyright 2025. All Rights Reserved by MedPath